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ABSTRACT
Despite the growing body of knowledge showing that testosterone (T) may not 
significantly affect tumor progression in hypogonadal patients treated for prostate 
cancer (Pca), the use of this hormone in this population still remains controversial. 
The effects of continuous or pulsed T stimulation were tested in vitro and in vivo 
on androgen-sensitive Pca cell lines in order to assess the differential biological 
properties of these two treatment modalities. Pulsed T treatment resulted in a 
greater inhibition than continuous T supplementation of tumor growth in vitro and 
in vivo. The effects of pulsed T treatment on tumor growth inhibition, G0/G1 cell 
cycle arrest, and tumor senescence was more pronounced than those obtained 
upon continuous T treatments. Mechanistic studies revealed that G0/G1 arrest and 
tumor senescence upon pulsed T treatment were associated with a marked decrease 
in cyclin D1, c-Myc and SKp2, CDK4 and p-Rb levels and upregulation of p27 and 
p-ERK1/2. Pulsed, but not continuous, T supplementation decreased the expression 
levels of AR, p-ARser81 and CDK1 in both cellular models. The in vitro results were 
confirmed in an in vivo xenografts, providing evidence of a greater inhibitory activity 
of pulsed supraphysiological T supplementation than continuous treatment, both in 
terms of tumor volume and decreased AR, p-ARser81, PSA and CDK1 staining. The 
rapid cycling from hypogonadal to physiological or supra-physiological T intraprostatic 
concentrations results in cytostatic and senescence effects in preclinical models of 
androgen-sensitive Pca. Our preclinical evidence provides relevant new insights in 
the biology of Pca response to pulsed T supplementation.
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 69), pp: 113792-113806
                                                     Research Paper
Oncotarget113793www.impactjournals.com/oncotarget
INTRODUCTION
The number of subjects requiring Testosterone 
Replacement Therapy (TRT) secondary to aging or 
to pathological conditions is dramatically increasing 
[1]. However, a number of controversial aspects of 
TRT are currently under debate [2, 3]. One of them is 
the possibility to use the TRT in deeply hypogonadal 
patients successfully treated for prostate cancer (Pca). 
Despite a growing body of knowledge showing that 
testosterone (T) may not significantly affect tumor 
progression, the use of T in this clinical condition still 
remains controversial [2, 3]. A number of studies have 
investigated the relationship between endogenous 
T levels and the risk of Pca, but have failed to find a 
significant relationship [4–7]. This evidence was also 
supported by a large meta-analysis, which suggested no 
association between serum androgen levels and the risk 
of Pca development [8]. Current literature suggests that 
TRT can be given to symptomatic hypogonadal patients 
who have received successful radical prostatectomy 
or radiotherapy and are considered cured [9]. TRT can 
be started in the first year after radical prostatectomy 
and with serum PSA levels less than 1 ng/mL after 
radiotherapy [10, 11]. Differently, the role of TRT for 
men with untreated Pca managed by active surveillance 
remains more controversial [2]. Morgentaler proposed 
the “saturation theory” to explain why T does not directly 
affect Pca progression during TRT [9]. According to this 
theory, Pca growth may become insensitive to changes 
at physiological androgen levels due to saturation of 
the androgen receptor (AR) by circulating androgens. 
In agreement with this hypothesis, the intraprostatic 
androgen environment was found to be almost unaffected 
in hypogonadal or healthy men treated with exogenous 
T at low [12] or physiological doses [13]. However 
when the effect of increasing doses of exogenous T 
on the concentrations of intraprostatic androgens was 
investigated in a randomized double blind placebo 
controlled trial (RCT), it was evident that the average 
serum T concentrations during treatment positively 
correlated with both intraprostatic DHT and T after 12 
weeks of treatment [14]. These clinical data may be of 
interest in the light of biological evidence that suggests 
that prostate cancers have a biphasic response to tumor 
cell growth in androgen-sensitive Pca cells [15–18]. 
Androgen supplementation, in the range of picomolar 
concentrations, makes Pca cells extremely sensitive to 
androgens [16, 18]. Paradoxically, when tumor cells were 
exposed to T in the range of nanomolar concentrations, 
in line with those measured within the prostate when 
serum T approaches to supraphysiological levels [14] 
a decrease in cell proliferation was observed [19–21]. 
So, any treatment with exogenous T administration able 
to stably or transiently cause supraphysiological serum 
T concentrations may also increase the intraprostatic T 
concentrations in the range of inhibitory growth effect. 
The use of transdermal T gel or of other forms of systemic 
T delivery allow to obtain stable circulating androgen 
levels at the higher end of the normal range for T, where 
many clinicians target therapies for hypogonadal men. 
Differently, episodic pulsed TRT may be an attractive 
therapeutic option with respect to the traditional 
continuous TRT especially if supraphysiological serum T 
concentrations have to be reached. However, the clinical 
efficacy of this type of treatment as well as its impact on 
Pca biology still remain to be studied. Our preclinical 
study was specifically built to investigate whether the 
rapid cycling from intraprostatic T concentrations typical 
of hypogonadism to physiological or supra-physiological 
concentrations may affect some biological parameters 
associated with aggressive behavioral properties of 
preclinical models of prostate cancer.
RESULTS
Pulsed testosterone supplementation results in 
higher decrease of prostate cancer cell growth 
rate with respect to continuous T treatment
It has been previously shown that continuous T 
treatment exerts a biphasic effect on the proliferative 
responses of prostatic cancer cell lines in vitro, inducing 
proliferation at concentrations corresponding to those in 
the cultured medium supplemented with 10% FBS, and 
inhibition at higher concentrations [15]. For this purpose, 
tumor cells were treated under both continuous or 
episode-like T treatments. In Figure 1A and 1B we report 
the schematic representation of episode-like treatment 
protocol. In agreement with these data we found that 
LNCaP and 22rv1 cells, continuously treated with 3.3, 
5.2 and 17.2 nM T for 48 h were growth inhibited at the 
highest T concentration (17.2 nM) (Figure 1C-1D). To 
investigate whether pulsed T treatment could affect the 
growth of androgen sensitive Pca cells, cultures were 
treated for 48 h with pulsed T (5.3 nM or 17.2 nM). Pulsed 
T treatment resulted in a significant growth inhibition both 
in LNCaP (67% and 75% at the concentration 5.3 nM and 
17.3 nM, respectively) and CW22Rv1 cells (52% and 56% 
at the concentration 5.3 nM and 17.2 nM, respectively) 
with respect to mock pulsed control cells. Interestingly, 
the pulsed T treatment resulted in a significant growth 
inhibition with respect to continuous T treatment 
concentrations that was also evidenced by the decrease 
of PCNA levels only in the pulsed T treatments both in 
LNCaP and in CW22RV1 cells (Figure 1E-1F).
T treatment does not induce apoptosis and 
autophagy in Pca cells
To understand if the anti-proliferative effect of 
pulsed T treatment was due to PCa cell death, cells were 
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stained with the Annexin V–Alexa Fluor® 488conjugate 
and Propidium iodide (PI) (Figure 2A-2B). We found 
that the percentage of Annexin V positive tumor cells 
undergoing apoptosis was not influenced by treatment 
with pulsed or continuous T treatment when compared 
to cell grown in 10% FBS (Figure 2A-2B), as well as 
cleaved caspase-3 levels were not influenced by T 
treatments (Figure 2C-2D). We also checked if autophagy 
might be induced when tumor cells were cultured with 
continuous or pulsed T treatments by analyzing the levels 
of Beclin-1 and p62 [22]. As shown in Figure 3, however, 
protein levels of these two autophagy markers did not 
change in T stimulated samples compared to control, 
suggesting that growth inhibition by pulsed T was not 
mediated by autophagy.
Testosterone supplementation induces G0/G1 
arrest and tumor senescence
We next determined whether cell cycle progression 
of PCa cells was affected by pulsed or continuous T 
supplementation. LNCaP treated for 48 hrs with pulsated 
T (5.2 and 17.2 nM) showed an increase of G0/G1 
population accompanied by a decrease of cells in both S 
and G2/M phases (Table 1) with respect to control (10% 
FBS). Differently, tumor cells, continuously treated with 
3.3, 5.2 and 17.2 nM T for 48 h showed and increased 
G0/G1 population at the highest T concentration (17.2 
nM) (Table 1). Also CW22Rv1 tumor cells showed a G0/
G1 arrest after pulsed T treatments (5.2 and 17.2 nM), 
however continuous treatment induced G0/G1 arrest 
only at higher T concentrations (17.2 nM) (Table 1). 
Figure 1: Schematic representation of pulsed T supplementation at physiological (A) or supraphysiological (B) T concentrations. In the 
pulsed experiments tumor cells were routinely grown in regular medium supplemented with 10% FBS and T at the concentration of 3 
nM. In a time frame of 48 hours these cells underwent 6 cycles of T pulsing. Each cycle lasted for 8 hours and was arranged as follows: 
T concentration was boosted from 3.3 nM to 5.2 nM (panel A) and to 17.2 nM (panel B) for 2 hours. Then, T concentration was reduced 
to 3 nM and maintained at this concentration for the remaining 6 hours. Growth at 48 hours of LnCaP (C) and CW22rv1 (D) cells treated 
with continuous or pulsed Testosterone The bars show the mean and SD of 36 replicates. Student-Newman-Keuls test for all pairwise 
comparisons in CW22rv1 and LnCaP cells at 48 hours after treatment. Expression levels, by western blot analysis, of PCNA in LnCaP (E) 
and CW22rv1 (F) tumor cells tumor cells treated with continuous or pulsed Testosterone for 48 hours.
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Figure 2: Percentage of live (Annexin V negative/PI negative cells), apoptotic (AnnexinV positive/PI negative cells) and dead (AnnexinV 
positive/PI positive cells or AnnexinV negative/PI positive cells) cells in LnCaP (A) and CW22rv1 (B) cell populations treated with 
continuous or pulsed Testosterone for 48 hours. The bars show the mean and SD of 36 replicates. Student-Newman-Keuls test for all 
pairwise comparisons in CW22rv1 and LnCaP cells at 48 hours after treatments. Expression levels, by western blot analysis, of pro-
caspase-3 and cleaved caspase3 in LnCaP (C) and CW22rv1 (D) tumor cells tumor cells treated with continuous or pulsed Testosterone 
for 48 hours.
Figure 3: Autophagy assessment. Expression levels, by western blot analysis, of beclin-1 (A, B) and p-62  (C, D) in CW22rv1 and 
LnCaP tumor cells treated with continuous or pulsed Testosterone for 48 hours.
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Interestingly, in both cellular models, the effect on G0/
G1 arrest was more pronounced in the pulsed treatments, 
without a concentration-dependent effect. Since 
growth arrest in the G0/G1 phase of the cell cycle can 
be associated to cellular senescence [24], we studied 
the effects of T treatments in inducing senescence in 
LNCaP and CW22rv1 cells. Activity of β-galactosidase, 
an enzyme that marks the senescence process [20], was 
thus assessed during T treatments. In LNCaP tumor cells, 
both continuous and pulsed T treatments induced cellular 
senescence, as shown by the increase in β-galactosidase 
activity with respect to control untreated cells (Figure 4A), 
while CW22Rv1 cellular senescence was induced only by 
continuous high T (17.2 nM) treatment and by pulsed T 
treatments (5.2 and 17.2 nM) with respect to the control 
untreated cells (Figure 4B).
To explore the molecular mechanism underlying 
the arrest of tumor cells in G0/G1 phase, we assessed 
the expression levels of the cell cycle inhibitors p16 and 
p27, in pulsed or continuous T treatments (Figure 4C-
4D). Pulsed, but not continuous, T treatments induced an 
increase of p16 p27 in LNCaP cells (Figure 5C), while in 
CW22rv1 cells both pulsed T treatment and continuous 
T treatment induced a strong increase of p27 and to a 
lesser extent an increase of p16 levels (Figure 4D). 
We also found that S-phase kinase-associated protein 
2 (Skp2), a protein involved in p27 ubiquitylation and 
degradation, inversely correlated with p27 both in 
LNCaP and CW22Rv1 tumor cells. Interestingly, Skp2 
levels were down-regulated by continuous or pulsed T 
treatments both in LNCaP and in CW22Rv1; although in 
these latter the continuous T treatment was effective only 
at 17.2 nM T concentration (Figure 4A-4B). We next 
investigated if T treatment was also affecting cyclin-D 
levels [28]. By western blot analysis we found that 
pulsed T stimulation strongly down-regulated cyclin D1 
and c-Myc levels both in LNCaP and CW22Rv1 cells. In 
the latter, similarly to Skp2, only high T concentration 
(17.2 nM) was also able to reduce cyclin D1 and c-Myc 
levels compared to the control (Figure 4E-4F). Finally, 
we evaluated CDK4 and p-RB expression upon pulsed 
or continuous T treatment. As shown, the levels of these 
two mediators were strongly down-regulated upon pulsed 
T treatments both in LNCaP tumor cells (Figure 4G) and 
in CW22rv1 tumor cells (Figure 4H).
T treatments results in androgen receptor down-
modulation via CDK1 modulation
Since we found that PCa cells were growth inhibited 
and arrested in G0/G1 of the cell cycle by T treatments, we 
investigated if AR expression could also be modulated by 
Table 1: Cell cycle analysis at 48 hours of treatment
LnCap tumor cells
Treatment Groups
Phases of cell cycle
G0/G1 S G2/M
Regular Medium with 10% FBS 63%+/-10% 22%+/- 6% 15%+/- 4%
Continuous T treatment (3.3 nM) 64%+/-8% 16%+/-8% 22% +/-6%
Continuous T treatment (5.2 nM) 69%+/- 4% 16%+/- 3% 15%+/-8%
Continuous T treatment (17.2 nM) *72%+/-4% 18%+/- 5% 10%+/-2%
Pulsed T treatment (5.2 nM) *89% +/-12% 6%+/- 3% 5%+/-2%
Pulsed T treatment (17.2 nM) *91%+/-8% 4%+/- 2% 5%+/-3%
*P<0.05 vs 10% FBS.
CW22RV1 tumor cells
Treatment Groups
Phases of cell cycle
G0/G1 S G2/M
Regular Medium with 10% FBS 58% +/-6% 22% +/- 3% 20% +/- 5%
Continuous T treatment (3.3 nM) 60% +/- 8% 15% +/-6% 23%+/-3%
Continuous T treatment (5.2 nM) 61% +/- 5% 24% +/- 4% 16% +/- 5%
Continuous T treatment (17.2 nM) *67% +/-2% 20% +/- 6% 13% +/- 3%
Pulsed T treatment (5.2 nM) *82% +/-10% 22% +/- 7% 5%/3%
Pulsed T treatment (17.2 nM) *83% +/-9% 14% +/- 4% 5% +/-2%
*P<0.05 vs 10% FBS.
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pulsed or continuous T concentrations. As shown in Figure 
5 (panels A-B) we found that pulsed T supplementation 
induced a sharp decrease of AR protein levels in both cell 
lines and, as expected, of the AR downstream target prostate-
specific antigen (PSA) (Figure 5A-5B). Phosphorylation 
of AR in Ser-81 is one of the most important mechanisms 
that increase AR protein stabilization and trans-activation 
ability [29, 30, 31]. In order to investigate if AR down-
regulation might be related to decreased AR stability we 
probed protein extracts from LNCaP and CW22Rv1 treated 
with pulsed or continuous T concentrations. We found 
that both LNCaP and CW22rv1 cells exposed to pulsed T 
treatment (Figure 5A-5B) showed a marked reduction of 
p-ARser81 levels, while only continuous treatment with high 
T (17.2 nM) concentration was able to reduce p-ARser81 
levels in CW22rv1 cells. Accordingly, when we evaluated 
the levels of cyclin-dependent kinase 1 (CDK1), the kinase 
that phosphorylates Ser81 of AR, we found that pulsed but 
not continuous T treatment decreased CDK1 expression in 
both cell lines.
Literature data indicate that high levels of p-ERK1/2 
signaling may inversely correlate with AR expression and 
result in G0/G1 phase cell cycle arrest in LNCaP cells 
[32]. Additionally, the G0/G1 growth arrest was related to 
Figure 4: Tumor senescence assessment. The content of β–Galactosidase was assessed by a specific ELISA kit in LnCaP (A) and 
CW22rv1 (B) tumor cells treated with continuous or pulsed Testosterone for 48 hours. The β–Galactosidase content was expressed as 
percent versus control (cells cultured in regular medium supplemented with 10% FBS). The bars show the mean and SD of 36 replicates. 
Student-Newman-Keuls test for all pairwise comparisons in 22rv1 and LnCaP cells at 48 hours after treatments. Expression levels, by 
western blot analysis, of p27, p16, SKp2 (C, D), cyclin-D1, c-myc (E, F), CDK4 and p-RB (G, H) in LnCaP and CW22rv1 tumor cells 
treated with continuous or pulsed Testosterone for 48 hours.
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neuroendocrine differentiation, a biological event related 
to androgens signaling abrogation [32]. When the levels 
of p-ERK1/2 were assessed upon T treatments, the pulsed 
treatments increased the phosphorylation levels of ERK1/2 
in both cell lines with respect to continuous treatments 
(Figure 5C-5D). No effect on ERK1/2 phosphorylation 
levels was observed when tumor cells were exposed to 
supraphysiological continuous T concentrations with 
respect to tumor cells cultured in 10% FBS medium 
(Figure 5C-5D). Interestingly, no changes in NSE levels 
was found across the continuous and pulsed T treatments. 
(Figure 5C-5D).
Growth-inhibitory activity of pulsed 
supraphysiological T supplementation on a 
prostate cancer xenograft model in nude mice
We next evaluated if continuous or pulsed 
supraphysiological T supplementation were effective in 
reducing PCa proliferation in vivo in xenograft models. 
Although CW22rv1 cells showed a lower sensitivity to 
continuous T treatment compared to LNCaP, they were 
equally sensitive to pulsed T treatment, and since they 
represent a primary prostate cancer-derived cell line, we 
selected these cells to perform xenografts experiments. 
CW22rv1 cells were subcutaneously inoculated in 6 
weeks-old castrated male immunodeficient CD1-nu/nu 
mice. Serum total T was measured in all animals from the 
hypogonadal or continuous treatment group two days after 
silastic tubes implantations and at the end of experiments 
(after 14 days) by cardiac puncture. Serum T level (ng/
mL; mean ± SD) was higher in the supraphysiological T 
continuous group (23.2 ± 2.2) than in hypogonadal group 
(1.92 ± 0.34). Differently, in the supraphysiological pulsed 
T group, serum T was measured at 2 and 5 hours during the 
first single cycle of treatment. In this group, serum T level 
(ng/mL; mean ± SD) was at 31.4 ng/mL (± 3.1) and 2.1 (± 
3.1) at 2 and 5 hours post injection confirming the rapid 
Figure 5: Expression levels, by western blot analysis, of AR, PSA p-ARser81, CDK1, p-ERK1/2, total ERK1/2 and NSE in 
LnCaP (A and C) and CW22rv1 (B and D) tumor cells treated with continuous or pulsed Testosterone for 48 hours.
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T cycling from supraphysiological to hypogonadal serum 
T levels. A significant reduction in tumor volume was 
found after 14 days of treatment in the supraphysiological 
pulsed T group versus the supraphysiological continuous 
T or hypogonadal groups, as well as when comparing 
the continuous supraphysiological T group versus 
hypogonadal groups (Figure 6A). The decrease of tumor 
volume was paralleled by a decrease of tumor weight 
in T-treated mice (Figure 6B) and both the parameters 
correlated with increased tumor fibrosis as demonstrated 
by trichromic stain (Figure 6C). By immunohistochemical 
staining we found that positivity for AR, p-ARser81, PSA 
and CDK1 was strongly reduced in xenografts exposed 
to pulsed treatments (Figure 6C right panels), while the 
expression levels of these markers were unchanged upon 
continuous T treatment or in hypogonadal condition 
(Figure 6C left and middle panels).
DISCUSSION
Testosterone is not the cause of prostate cancer, but 
it is considered essential for the growth of this tumor. The 
question whether testosterone replacement therapy is a 
risk factor for PCa remains however controversial. The 
serum T level required for maximum androgen receptor 
binding may be as low as 2–4 nM (60–120 ng/dL) [23]. 
Thus, above this range of concentrations, T may not 
affect tumor biology or other cellular androgen receptor-
dependent mechanisms, as supported by clinical studies 
showing that cell proliferation markers do not change when 
serum T levels increase after exogenous T treatment in 
comparison to subjects treated with placebo [12]. However, 
a considerable part of the global scientific community 
remains skeptical regarding the use of TRT in men 
suffering from a hypogonadal condition and successfully 
treated for Pca. These negative attitudes may be justified 
by the relatively low number of clinical and preclinical 
studies that specifically dealt with how T affects Pca 
biology at concentrations mimicking those found during 
TRT. The main clinical objective of all T formulations used 
during TRT is to obtain a sustained and continuous serum T 
level in the range of middle/normal values [3]. On the other 
hand, some authors have studied the pharmacodynamic and 
pharmacokinetic parameters of T administered in a pulsed 
way by the sublingual (SL) route [37–39]. They found that 
the fluctuation in T during SL administration resembled 
endogenous episodic secretion, with a potentially favorable 
safety profile [33–36].
Pulsed T treatment has not been investigated, with 
only some preclinical reports investigating the influence 
of single T boost on the biological behavior of Pca cells 
with different sensitivity to manipulation by androgens 
[33-34, 40, 41]. The main novelty with respect to the 
current literature is that Pca cells were exposed to a rapid 
cycling of T both in vitro and in vivo. When Pca cells 
were treated with continuous T at concentrations found 
within the prostate tissue of men under TRT (5.2 nM) no 
change in tumor cell proliferation was observed compared 
to tumor cells grown in regular medium or under T 
concentrations (3.3 nM) found within the prostate tissue 
of men suffering from hypogonadism. Moreover, when T 
was supplemented to tumor cells mimicking physiological 
intraprostatic concentrations, but in a pulse-like manner, 
a significant decrease in tumor cell proliferation was 
observed with respect to tumor cells grown under 
continuous T treatments at a concentration found within 
prostate tissue of men suffering from hypogonadism (3.3 
nM). Additionally, when both pulsed and continuous T 
were used at supraphysiological concentrations (17.2 
nM), the inhibitory effects on cell proliferation rate were 
more sustained than those observed during the same 
treatment modalities at lower T concentrations (3.3 
nM and 5.2 nM). Our results are in keeping with other 
evidence. There are, in fact, a number of studies that 
indicate that T has a biphasic effect on tumor cell growth 
in androgen-sensitive Pca cells [15, 40, 41]. Testosterone 
supplementation, in the range of picomolar concentrations, 
makes Pca cells extremely sensitive to androgens [15, 40, 
41]. Paradoxically, when exogenous T was supplemented 
in the range of nanomolar concentrations, a decrease 
in cell proliferation was observed [42–44]. The main 
consequence of our data is that Pca cells exposed to T 
concentrations similar to those observed during TRT did 
not acquire more aggressive biological behaviors and 
conversely, under pulsed treatment, have been found 
inhibited in their growth.
Another interesting finding we found is that pulsed 
treatments resulted in a concentration independent 
cell growth arrest of LNCaP and CW22rv1 cells with 
concomitant cell cycle arrest in the G0/G1 phase. These 
effects were not related with apoptotic events. The 
dissection of underlying molecular mechanisms showed 
that G1 arrest by pulsed T treatments involves a decrease 
in SKp2 coupled with increased p21, p27 and p-ERK1/2. 
Other mediators clearly involved in the G0/G1 cell cycle 
arrest under pulsed T treatment were cyclin D1 and 
c-Myc [45]. In controlled cell growth, cyclin D1 leads to 
phosphorylation of RB which, in turn, mediates the release 
of E2F [46] with activation of c-Myc and cell proliferation 
[47]. This evidence suggests that a significant decrease 
in protein levels of cyclin D1 and c-Myc upon pulsed T 
treatments is an adjunctive mechanism able to exert an 
inhibitory effect in both LNCaP and CW22rv1 cells. The 
implications of T-driven modulation of these mediators 
may be of particular significance in hormone-sensitive Pca 
cells because cyclin D1, c-Myc and SKp2 are associated 
with androgen-stimulated growth.
Another way by which pulsed and continuous T 
treatments influence the biology of Pca cells is linked 
to tumor senescence induction. Senescence represents 
an irreversible form of cell-cycle arrest that can act as 
an important tumor-suppressive mechanism and the 
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literature indicates that growth arrest in the G0/G1 phase 
of the cell cycle and tumor senescence may be closely 
correlated [16]. In this regard, Skp2, a critical component 
of the Skp2–SCF complex, acts as an E3 ligase to target 
p27 for ubiquitylation and degradation [25, 26]. Recent 
studies also suggest that Skp2 inactivation induces tumor 
senescence via p21 and p27 and that this phenomenon 
may be partially under androgenic control in Pca [24, 
25]. In agreement with these findings, we found that 
tumor senescence, as measured by the surrogate marker 
β-galactosidase, was significantly increased in Pca cells 
treated with pulsed or continuous T supplementation 
compared to controls. Testosterone-mediated tumor 
senescence paralleled with decreased SKp2 and increased 
p21 and p27 expression [27].
Another interesting and new finding of our study 
concerns the modulation of AR expression which 
has a central role in PCa biology. AR expression was 
selectively down-regulated when tumor cells were treated 
with both pulsed physiological or supraphysiological 
T concentrations. Conversely the expression of this 
nuclear receptor was almost unaffected under continuous 
T supplementation. The AR modulation was paralleled 
by the modulation of p-ARser81, CDK1 and p-ERK1/2, 
three mediators involved in stabilization of AR [31, 32]. 
Studies have shown that CDK1 is a p-ARSer-81 kinase and 
maintains AR expression via Ser-81 phosphorylation. 
We speculate that the rapid cycling T levels affects 
CDK1 and p-ARser-81 expression decreasing the AR 
protein stability with consequent effects on AR protein 
expression levels. The reasons why T may differentially 
affect these mediators under continuous or pulsed 
treatment modalities remains to be elucidated although 
the differential increase of p-ERK1/2 upon different T 
treatment regimens may explain this interesting and new 
phenomenon. In this regard, literature data indicate that 
high levels of p-ERK1/2 signaling may inversely correlate 
with AR expression and result in G0/G1 phase cell cycle 
arrest in LNCaP cells [32]. Some of these in vitro results 
were confirmed in a xenograft model in vivo, providing for 
Figure 6: Mice xenografted with CW22rv1 cells were treated with T as described in materials and methods. (A) 
Tumor volume was assessed at the beginning of the treatment and every 2 days thereafter. *P<0.001 vs Hypogonadal group; ° P<0.001 vs 
Supraphysiological Continuous T Supplementation (B) Tumor weight was assessed at the end of the treatment. *P<0.001 vs Hypogonadal 
Group; ° P<0.001 vs Supraphysiological Continuous T Supplementation. (C) Masson’s trichrome, AR, PSA, p-ARser81 and CDK1 staining 
in sections from mice xenografted with CW22Rv1 tumor cells.
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the first time the concept of proof that supraphysiological 
pulsed T supplementation induces a significant reduction 
in both tumor volume and AR, p-ARser81, PSA and CDK1 
staining with respect to supraphysiological continuous T 
supplementation or T levels in the range of hypogonadism.
Our preclinical evidence may have implications 
for the future clinical studies in the field of TRT. 
Physiological intraprostatic T concentrations, achieved 
by continuous T supplementation, appear to not adversely 
affect the tumorigenic potential of Pca cells. This finding 
may suggest that men suffering from hypogonadism and 
successfully treated with Pca may achieve physiological 
serum and intraprostatic T concentrations with limited, if 
any, risks of T-dependent tumor progression. Additionally, 
when supra-physiological intraprostatic T concentrations 
were achieved, a significant reduction in the tumorigenic 
potential of Pca cells was observed. On the other 
hand, when both physiological or supra-physiological 
intraprostatic T concentrations were achieved by the 
pulsed T supplementation, a dramatic decrease in some 
tumorigenic properties was observed suggesting that this 
type of supplementation may decrease the tumorigenic 
potential of Pca cell more effectively than continuous 
treatments. However, the real efficacy and safety of the 
pulsed T treatment regimens in a clinical setting must be 
defined and proved using well-designed clinical trials.
This study has a number of limitations. Although 
the cellular models used represent two well known 
models of androgen dependent (LnCaP cells) and primary 
aggressive Pca (CW22rv1 cells) we realize that they 
may have unique biological behaviours and molecular 
characteristics with limited possibility to generalize 
our evidence to primary/localized/hormone naïve Pca. 
Another potential limit is that we can only speculate that 
supraphysiological serum T concentrations can really 
result in similar changes in the androgens within human 
prostate tissue. Two studies provide empirical evidence 
concerning the androgen levels within prostate tissue in 
the setting of low or physiological doses of exogenous 
T supplementation [12, 13]. These studies show that 
prostatic androgens are not materially changed, at least at 
the circulating androgen levels achieved in these studies 
(physiological serum T levels) although a slight increasing 
trend was observed in the intraprostatic T concentrations 
[12, 13]. This evidence fits well with the saturation 
theory, which postulates that Pca growth may become 
insensitive to changes at serum physiological androgen 
levels due to saturation of the AR [2, 9]. However, the 
paradigm of saturation theory is not completely satisfied 
when serum T concentration approaches the upper limit 
of the normal range. A very recent RCT investigated the 
dose-dependent effects of increasing doses of exogenous 
T on intraprostatic androgens concentrations in human 
males [14]. In this study it was evident that the average 
serum T concentrations during dose-dependent treatment 
positively correlated with both intraprostatic DHT and 
T after 12 weeks of treatment [14]. Interestingly the 
correlation of serum T with intraprostatic T disappeared 
if men with very low or very high serum T levels were 
excluded from the analysis. This evidence may support 
our assumption that the T concentrations used in our study 
may be potentially achievable within prostate in men with 
supraphysiological serum T levels. However, whether the 
intraprostatic androgens may be rapidly cycling during 
a pulsed exogenous T supplementation remains to be 
proven. In this regard the most interesting evidence we 
provide is that the rapid cycling of serum T levels obtained 
during pulsed T supplementation may indeed result in a 
measurable antitumor activity in a human xenograft 
model of primary aggressive Pca. With these limitations 
we provide highly relevant new insights, both in vitro and 
in vivo, into the biology of tumor response to pulsed T 
supplementation. The rapid cycling from hypogonadal 
to physiological and supraphysiological T intraprostatic 
concentrations results in an antitumor effect in preclinical 
models of Pca. Whether any of this evidence is clinically 
relevant remains to be proven.
MATERIALS AND METHODS
Reagents and tumor cell lines
All of the materials for tissue culture were purchased 
from Hyclone (Cramlington,). Plasticware was obtained 
from Nunc (Roskilde, Denmark). Anti-cyclin D1, anti-
PCNA, anti-β-actin, anti-pro-caspsase-3, anti-cleaved 
caspase-3, anti-SKp2, anti-p27, anti-AR, anti-p-ERK1/2, 
anti-total ERK1/2, anti-NSE, anti-beclin-1, anti-CDK4 and 
p62 antibodies were purchased from SantaCruz (SantaCruz, 
CA). Anti-c-Myc and anti-pARser-81 was purchased from 
Cell Signaling and Merk Millipore (Billerica, MA, USA). 
Anti-Rb (phospho S780) (ab47763) antibody was purchased 
from Abcam. Testosterone was purchased from Sigma-
Aldrich (Italian distributor, Milan, Italy) and dissolved 
and stocked in 100% methanol. MTT was purchased from 
Sigma-Aldrich (Italian distributor, Milan, Italy). LNCaP and 
CWR22Rv1 prostate cancer cell line was obtained from the 
American Type Culture Collection (Manassas, VA, USA). 
Cells were cultured in Dulbecco's Modified Eagle's medium 
(DMEM) or Roswell Park Memorial Institute (RPMI) 1640 
supplemented with glutamine, pyruvate, gentamycin (Life 
Technologies) and 10% heat-inactivated fetal bovine serum 
(10% FBS) (JRH Biosciences; Lenexa, Kansas, United 
States) and transferred to medium 10% charcoal strip serum 
(CSS) before T treatment. To minimize the risk of working 
with misidentified and/or contaminated cell lines, we later 
stocked the cells used in this report at very low passages and 
used at <20 subcultures. Periodically, DNA profiling using 
the Gene Print 10 System (Promega Corporation, Madison, 
WI) was carried out to authenticate cell cultures, comparing 
the DNA profile of our cell cultures with those found in 
GenBank.
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In vitro T treatments
Studies estimate that intraprostatic T concentrations 
in men suffering from hypogonadal conditions are, on 
average, 3.3 nM while the concentrations of this hormone 
during TRT treatment are 5.2 nM [12]. In contrast, no 
empirical evidence exists regarding the intraprostatic 
concentrations in men with supra-physiological serum T 
concentrations. Therefore, 3-fold higher T concentrations 
(17.2 nM) with respect to the physiologic concentration 
of 5.2 nM measured in the study of Marks [12] seems 
to be reasonable and was chosen as intraprostatic supra-
physiological T concentration.
In vitro pulsed T supplementation
The schematic representation of pulsed T 
supplementation is shown in Figure 1. It was built 
on pharmacodynamic data obtained in a study 
using sublingual administration of testosterone 
2-hydroxypropyl-β-cyclodextrin inclusion complex. [33, 
34]. In this study, after the administration of a single 
dose, acute pharmacodynamic changes were observed 
with supraphysiological serum concentration of T and 
a rapid decline to below the normal range at 2 h. In our 
experimental setting, the pulsed experiments tumor cells 
were routinely growth in regular medium supplemented 
with 10% FBS and T at the concentration of 3 nM. In at 
time frame of 48 hours these cells underwent 6 cycles of 
rapid T cycling arranged as follow: T concentration was 
boosted from 3.3 nM to 5.2 nM (Figure 1A) or to 17.2 
nM (Figure 1B) for 2 hours. Then, T concentration was 
reduced to 3 nM and maintained at this concentration 
for the remaining 6 hours. After each modification of T 
concentration, tumor cells were gently washed by PBS 
in order to avoid any accumulation of T in the culture 
medium.
In vitro continuous T supplementation
Treatments were arranged as follows: (i) T was 
added to medium at the concentration of 3.3 nM and 
maintained for 48 hours. (ii) T was added to medium at 
the concentration of 5.2 nM and maintained for 48 hours. 
(iii) T was added to medium at the concentration of 
17.2 nM and maintained for 48 hours. Cells exposed to 
continuous treatments were handled as cells exposed to 
pulsed T treatments. Specifically, in order to minimize the 
risk that some biological effects observed during pulsed 
T supplementation were imputable to the rapid cycling 
of other growth factors contained in the 10% FBS or 
to an external stress due to the replacement of medium 
or to PBS washing, the culture medium of tumor cells 
exposed to continuous T concentrations was replaced and 
washed identically to what was done during the pulsed T 
supplementation.
Cell viability measured by MTT assay
Tumor cells were treated with T as previously 
described. After these treatments, media were removed and 
100 μl of MTT was added at the concentration of 0.5 mg/
ml; dishes were processed according to the manufacturer’s 
instructions. Results were expressed as a percentage of 
vital cells with respect to controls. All experimentations 
were performed at least three times.
Annexin-V analysis
To assess apoptosis, cells were treated with 
continuous or pulsed T in 6-well plates at a density of 1 
X 105 cells per well. After incubation for 48 h, cells were 
harvested and washed three times with PBS. Cells were 
either fixed with 70% ethanol for cell-cycle analysis or 
stained with the FITC Annexin V Apoptosis Detection Kit 
(Life Technologies) for Tali image-based apoptosis assay 
(Life Technologies). For detection of apoptosis, cells were 
incubated with Annexin V and Propidium Iodide (PI) for 
20 min at room temperature in the dark. Annexin V and 
PI stained live cells were then loaded on a Tali Cellular 
Analysis Slide for Tali image-based apoptosis analysis. 
Cells stained with Annexin and/or PI were counted and 
each experiment was performed in triplicate.
Cell cycle analysis
After appropriate treatments, cell viability was 
analyzed by the Cell Titer 96 assay (Promega, Madison, 
WI) and adherent cells were trypsinized, pooled with the 
culture supernatant containing the apoptotic cells already 
detached from the dish and centrifuged. Cells (1x106) 
were washed in PBS and fixed for 30 min by the addition 
of 1 ml of 70% ethanol. After 30 min, the cells were 
pelleted by centrifugation at 720 g for 5 min, resuspended 
in 1 ml of DNA staining solution (PBS containing 200 
mg/ml RNase A, 20 mg/ml propidium iodide plus 0.1% 
Triton X-100) and then stained by incubation at room 
temperature for 60 min. All cells were measured on a 
FACScan flow cytometer (Becton-Dickinson, Oxford, 
UK) and analyses using Cell Quest software (Becton-
Dickinson). All experimentations were performed in 
triplicate and repeated at least three times.
Senescence assay
Senescence was assessed by a specific assay kit 
measuring β-galactosidase activity in cultured mammalian 
cells. The β-galactosidase-associated senescence marker 
was tested as follows: cells were seeded at 5x104 cells per 
well in 96-well plates and allowed to attach overnight. 
The following day, tumor cells were treated as described 
above. Forty-eight hours later, tumor cells were washed 
twice with phosphate buffered saline (PBS) at pH7.2. 
β-galactosidase Assay Reagent (100 μl) was added to 
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each well and an incubation for 30 min at 37°C was 
performed. A β-galactosidase stop solution (100 μl) was 
added to each well and absorbance was measured at 
450 nm using a plate-reading spectrophotometer. The 
β-galactosidase content was expressed as percent versus 
control. All experimentations were performed in triplicate 
and repeated at least three times.
Western blot analysis
Cells and frozen tissues were washed with cold 
PBS and immediately lysed with 1 ml of lysis buffer (50 
mM HEPES, pH 7.5, 150 mM NaCl, 1% Triton X-100, 
1 mM EDTA, 1 mM sodium orthovanadate, 30 mM 
p-nitrophenyl phosphate, 10 mM sodium pyrophosphate, 
1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin 
and 10 μg/ml leupeptin). Lysates were electrophoresed in 
7% SDS-PAGE, and separated proteins transferred to a 
nitrocellulose membrane and probed with the appropriate 
antibodies using the conditions recommended by the 
antibody suppliers.
In vivo experimental models
Immunodeficient castrated male CD1-nu/nu mice, 
at 6 weeks of age, were purchased from Charles River 
(Milano, Italy). Castrated mice were chosen in order to 
minimize the interference that endogenous T levels could 
have during the exogenous T supplementation. Before 
manipulations, all mice were anesthetized with a mixture 
of ketamine (25 mg/ml) and xylazine (5 mg/ml). CW22rv1 
cells were grown to 80% confluence and harvested. Cells 
were re-suspended in serum free RPMI-1640 medium with 
penicillin and streptomycin, mixed 1:1 with Growth Factor 
Reduced (GFR) BD Matrigel Basement Membrane Matrix 
(BD Biosciences, Palo Alto, California). Using a cold 
syringe and 27-gauge needle, 5 × 106 CW22rv1 cells were 
subcutaneously injected into each lateral flank of nude 
mice. Mice were kept under sterile conditions, receiving 
sterile nutrition and water. Each group was composed of 
10 mice. When measurable tumors (80-130 mm3) were 
established animal treatments were started and were 
stopped 14 days after. Mice were sacrificed by carbon 
dioxide inhalation. All the experiments were approved and 
were carried out in accordance with the relevant guidelines 
and regulations established by the University of L’Aquila 
(Medical School and Science and Technology School 
Board Regulations, complying with the Italian government 
regulation n.116 January 27 1992 for the use of laboratory 
animals) which is in line with ARRIVE guidelines.
Testosterone supplementation in vivo
In the continuous T treatment experiments, the 
group named Supraphysiological continuous T was 
implanted subcutaneously with 2 mm silastic implants 
(inside diameter 1.98 mm, outside diameter 3.18 mm, 
wall thickness 0.61 mm) (Dow Corning Corp. Midland, 
MI) containing Testosterone propionate (Tp) (Sigma–
Aldrich, St Louis, MO, T1875) and sealed with silicone 
glue (Dow Corning Corp.). These silastic implants 
were chosen on the basis of the method of calculating 
release dosage related at the surface area of the T-filled 
silastic tube [48]. According to this prediction model, 
the estimation of serum T concentration in the implanted 
mice should be around the range of supraphysiological 
T levels [20 ng/ml plasma (69.2 nM)] of an adult (> 
40years old) human male. The hypogonadal group, was 
implanted subcutaneously with 1.0 cm silastic implants 
(0.078 mm inner diameter, 0.125 mm outer diameter; 
Dow Corning Corp. Midland, MI) containing Tp (Sigma–
Aldrich, St Louis, MO, T1875) and sealed with silicone 
glue (Dow Corning Corp.). Based on the same method 
of calculating release dosage based on the surface 
area of the T-filled silastic tube [48] the estimation of 
serum T concentrations in the implanted mice should 
be of around 2 ng/ml plasma (6.9 nM), which is in the 
range of T levels of hypogonadal adult (> 40years old) 
human male. In the pulsed T experiments, T (2.5 g) 
and 2-hydroxipropyl-β-cyclodextrin (25g) were stirred 
in distilled water (100 ml) at room temperature for 30 
minutes, filtered by a Millipore filter (0.45 μm) and then 
diluted to 200 ml with distilled water and freeze-dried. 
The resulting powder containing of T was dissolved in 
isotonic saline solution and injected subcutaneously, 
as already described [49]. In the pulsed T treatment 
experiments, T was injected subcutaneously every 8 
hours for 14 days. T administered as inclusion complex 
with 2-hydroxipropyl-β-cyclodextrin subcutaneously 
enters the circulation in pulsed like manner similar to 
the sublingual administration of a tablet containing 
testosterone (150 ng/kg):2-hydroxipropyl-β-cyclodextrin 
complex to a hypogonadal male [49, 33, 34]. The mice 
included in this group (supraphysiological pulsed 
T group) were also implanted with silastic tubes in 
order to obtain animals with T levels of a hypogonadal 
adult (> 40years old) human male. The use of silastic 
implants in this group was necessary in order to avoid 
that, after single subcutaneous T supplementations, the 
predicted levels of serum T levels dropped in the range 
of castration. The silastic tubes were implanted when 
measurable tumors (0, 8–1, 0 cm3) were established and 
the implants were maintained for 14 days.
Evaluation of treatment response in vivo
The evaluation of treatment response in vivo was 
evaluated as follows: (1) measurement of tumor volume 
during and at the end of experiments. Tumor volume was 
assessed by measurement every 2 days with a Vernier 
caliper (length × width). The volume of the tumor was 
expressed in mm3 according to the formula 4/3π r3;
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Histological and immunocytochemistry staining
Serial 3 μm sections were stained with Masson’s 
Trichrome in order to evaluate morphological aspects. 
For immunohistochemistry (IHC) analysis, sections 
were incubated for 40 minutes in methanol and 3% 
hydrogen peroxidase solution and then rinsed in PBS. 
Samples were incubated 10 minutes in buffered citrate 
0.01 M, pH 6, twice and rinsed in PBS. Sections were 
then treated with BSA (5%) for 10 minutes and finally 
incubated overnight with specific antibodies against, 
CDK1 (#ab8040; Abcam, Cambridge, UK), AR 
(#M3562; Dako UK Ltd.), pARS81 (#07-1375; Merk 
Millipore, Billerica, MA, USA), and PSA (#sc 7316, 
SantaCruz, CA) were diluted at 1:200, 1: 100, 1: 1000, 
1: 100, respectively. Samples were then rinsed with PBS 
for 5 minutes and incubated with a labeled streptavidin-
biotin- peroxidase conjugate kit (Dako LSAB plus, cod. 
K0675, Dako Cytomation, Milan, Italy). After rinsing in 
PBS for 10 minutes the sections were incubated with 3, 
3-diaminobenzidine-tetrahydrochloride (DAB, Sigma 
Aldrich) for 1–3 minutes. The specificity of immune 
reactions was revealed by the absence of the primary 
antibodies. Lastly, the samples were counterstained 
with Mayer’s Hematoxylin and observed under a 
photomicroscope Olympus BX51 Light Microscope 
(Olympus, Optical Co. Ltd, Tokyo, Japan). Observations 
were processed with an image analysis system (IAS, 
Delta system, Rome, Italy) and were independently 
performed in a blinded fashion.
Serum testosterone measurements
Elisa assay of serum testosterone levels were 
determined by and Enzyme Immunoassay (EIA) Kit for 
the in vitro quantitative determination of testosterone 
concentration was performed to measure the serum 
testosterone levels, without serum extraction, after 
silastic tube implantations. This kit was purchased from 
BioCheck, Inc. (Foster City, CA) (Cat. BC-1115) its 
minimum sensitivity for the detection of testosterone was 
of 0.05 ng/ml.
Statistics
Continuous variables were summarized as mean 
and standard deviation (SD). For continuous variables 
statistical comparisons between control and treated groups 
were established by carrying out the ANOVA test or by 
Student t test for unpaired data (for two comparisons). 
When the ANOVA test revealed a statistical difference, 
pair-wise comparisons were made by Student-Newman-
Keuls test. P values <0.05 were considered statistically 
significant. SPSS® version 10.0 was used for statistical 
analysis.
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